What is Acepodia?
Acepodia is a pioneering biotechnology company specializing in the development of first-in-class, off-the-shelf allogeneic cell therapies. At the core of its operations is the proprietary Antibody-Cell Conjugation (ACC) platform, which enables the linkage of tumor-targeting antibodies to immune cells, such as gamma delta T cells and natural killer (NK) cells. This technological innovation addresses critical gaps in cancer care by enhancing binding strength against tumors that express low levels of tumor antigens. By focusing on both hematologic and solid tumor cancers, Acepodia is effectively bridging the gap between laboratory research and clinical application, aiming to provide affordable and potent therapeutic options to a broad patient population. The company's leadership team, comprised of seasoned scientific experts, remains dedicated to advancing these novel antibody cell effector (ACE) therapies through rigorous clinical validation.
How much funding has Acepodia raised?
Acepodia has raised a total of $266M across 4 funding rounds:
Series A
$10M
Series B
$47M
Series C
$109M
Series D
$100M
Series A (2020): $10M, investors not publicly disclosed
Series B (2021): $47M led by DEFTA Partners, CDIB Capital International, The 8VC, and Ridgeback Capital Management
Series C (2021): $109M supported by Digital Mobile Venture
Series D (2023): $100M featuring Digital Mobile Venture
Key Investors in Acepodia
DEFTA Partners
DEFTA Partners is a global venture investment firm focusing on innovative technologies in healthcare and information technology, with a strong track record of supporting transformative therapeutics.
CDIB Capital International
CDIB Capital is a prominent Asian private equity investor specializing in middle-market growth capital and buyout transactions across the healthcare and technology sectors.
8VC
8VC is a venture capital firm that partners with entrepreneurs to build lasting technology companies, often focusing on deep-tech and life sciences innovations.
What's next for Acepodia?
With the recent infusion of capital, Acepodia is poised to transition into a more mature phase of its corporate lifecycle. The strategic focus will likely shift toward the acceleration of its clinical pipeline, specifically targeting the optimization of its off-the-shelf ACE therapies for broader commercial viability. As the company moves forward, the emphasis will remain on demonstrating superior potency and safety profiles in human trials, which are essential for regulatory approval and long-term market adoption. Furthermore, the firm is expected to leverage its strengthened balance sheet to enhance its manufacturing capabilities, ensuring that its innovative therapies can be scaled efficiently to meet global demand. This phase of development is critical for Acepodia as it seeks to establish itself as a leader in the next generation of cancer immunotherapy.
See full Acepodia company page
